VXRT – Vaxart, Inc.
VXRT — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
9.33
Margin Of Safety %
44
Put/Call OI Ratio
EPS Next Q Diff
-0.27
EPS Last/This Y
-0.61
EPS This/Next Y
-0.13
Price
0.61
Target Price
4.67
Analyst Recom
Performance Q
-15.61
Upside
N/A
Beta
1.14
Ticker: VXRT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | VXRT | 0.7999 | N/A | N/A | 0 |
| 2026-03-10 | VXRT | 0.7755 | N/A | N/A | 0 |
| 2026-03-11 | VXRT | 0.7722 | N/A | N/A | 0 |
| 2026-03-12 | VXRT | 0.7499 | N/A | N/A | 0 |
| 2026-03-13 | VXRT | 0.73 | N/A | N/A | 0 |
| 2026-03-17 | VXRT | 0.6695 | N/A | N/A | 0 |
| 2026-03-18 | VXRT | 0.635 | N/A | N/A | 0 |
| 2026-03-19 | VXRT | 0.63 | N/A | N/A | 0 |
| 2026-03-20 | VXRT | 0.6395 | N/A | N/A | 0 |
| 2026-03-23 | VXRT | 0.71 | N/A | N/A | 0 |
| 2026-03-24 | VXRT | 0.69 | N/A | N/A | 0 |
| 2026-03-25 | VXRT | 0.6782 | N/A | N/A | 0 |
| 2026-03-26 | VXRT | 0.67 | N/A | N/A | 0 |
| 2026-03-27 | VXRT | 0.64 | N/A | N/A | 0 |
| 2026-03-30 | VXRT | 0.6097 | N/A | N/A | 0 |
| 2026-03-31 | VXRT | 0.618 | N/A | N/A | 0 |
| 2026-04-01 | VXRT | 0.6294 | N/A | N/A | 0 |
| 2026-04-02 | VXRT | 0.61 | N/A | N/A | 0 |
| 2026-04-06 | VXRT | 0.6201 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | VXRT | 0.74 | -5.6 | - | -0.29 |
| 2026-03-10 | VXRT | 0.80 | -5.6 | - | -0.29 |
| 2026-03-11 | VXRT | 0.77 | -5.6 | - | -0.29 |
| 2026-03-12 | VXRT | 0.77 | -5.6 | - | -0.29 |
| 2026-03-13 | VXRT | 0.77 | -60.0 | - | -0.45 |
| 2026-03-17 | VXRT | 0.68 | -60.0 | - | -0.45 |
| 2026-03-18 | VXRT | 0.68 | -60.0 | - | -0.45 |
| 2026-03-19 | VXRT | 0.63 | -60.0 | - | -0.45 |
| 2026-03-20 | VXRT | 0.65 | - | - | -0.54 |
| 2026-03-23 | VXRT | 0.64 | - | - | -0.54 |
| 2026-03-24 | VXRT | 0.72 | - | - | -0.54 |
| 2026-03-25 | VXRT | 0.69 | - | - | -0.54 |
| 2026-03-26 | VXRT | 0.68 | - | - | -0.54 |
| 2026-03-27 | VXRT | 0.68 | - | - | -0.54 |
| 2026-03-30 | VXRT | 0.65 | - | - | -0.54 |
| 2026-03-31 | VXRT | 0.60 | - | - | -0.54 |
| 2026-04-01 | VXRT | 0.61 | - | - | -0.54 |
| 2026-04-02 | VXRT | 0.63 | - | - | -0.54 |
| 2026-04-06 | VXRT | 0.61 | - | - | -0.54 |
| 2026-04-07 | VXRT | 0.61 | - | - | -0.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
No data found
Last Quarter Act. EPS
0.24
Avg. EPS Est. Current Quarter
0.02
Avg. EPS Est. Next Quarter
-0.03
Insider Transactions
4.29
Institutional Transactions
Beta
1.14
Average Sales Estimate Current Quarter
65
Average Sales Estimate Next Quarter
50
Fair Value
0.88
Quality Score
84
Growth Score
41
Sentiment Score
35
Actual DrawDown %
94.5
Max Drawdown 5-Year %
-97.2
Target Price
4.67
P/E
Forward P/E
PEG
P/S
1.54
P/B
1.6
P/Free Cash Flow
EPS
-0.26
Average EPS Est. Cur. Y
-0.54
EPS Next Y. (Est.)
-0.67
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
-8.9
Return on Equity vs Industry %
7.7
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.2
EBIT Estimation
No data found for VXRT
Vaxart, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 65
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
VXRT
Latest News
—
Caricamento notizie per VXRT…
stock quote shares VXRT – Vaxart, Inc. Stock Price stock today
news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VXRT – Vaxart, Inc. yahoo finance google finance
stock history VXRT – Vaxart, Inc. invest stock market
stock prices VXRT premarket after hours
ticker VXRT fair value insiders trading